Amunix Announces Exclusive Agreements With Naia to Develop GLP-1 and GLP-2 XTEN(TM) Products
January 05, 2015 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Jan 5, 2015) - Amunix Operating Inc. (Amunix), a leader in the field of protein half-life extension, today announced a research and development partnership with...
Amunix Announces Option Exercise by Eli Lilly and Company for XTEN(TM) Product for People With Diabetes
December 17, 2014 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Dec 17, 2014) - Amunix Operating Inc. (Amunix), a leader in the field of protein half-life extension, today announced that its partner Eli Lilly and Company (Lilly)...
Amunix and PolyPeptide Enter Into Partnership to Produce XTEN(TM) Peptide Conjugates for Evaluation by Third Parties for Pharmaceutical Therapeutics
October 28, 2014 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Oct 28, 2014) - Amunix Operating Inc., and PolyPeptide Laboratories, Inc. (PPL) have entered into a partnership under which Amunix's proprietary recombinantly...
Amunix Signs a Services and Supply Agreement With the University of Nebraska-Lincoln to Produce GMP-Grade XTEN(TM) for Pharmaceutical Therapeutics
October 27, 2014 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Oct 27, 2014) - Amunix Operating Inc., a biotechnology company developing polypeptides which can be recombinantly fused or chemically conjugated to other peptides,...
Amunix and PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates in vivo Studies in American Chemical Society's Journal "Bioconjugate Chemistry"
July 23, 2014 08:05 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Jul 23, 2014) - Amunix Operating Inc., a biotechnology company developing hydrophilic, unstructured polypeptides which can be recombinantly fused or chemically...
Amunix Congratulates Versartis on Its Positive Phase 2a Results With VRS-317
June 30, 2014 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Jun 30, 2014) - Amunix Operating Inc., a biotechnology company developing a half-life extension technology for peptides, proteins and small molecules,...
Amunix Presents XTEN Half-Life Extension Technology at Next Generation Protein Therapeutics Summit
June 05, 2014 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - Jun 5, 2014) - Amunix Operating Inc. said today it is presenting unpublished data from its XTEN half-life extension technology development programs during two...
Amunix to Present Unpublished Data at Next Generation Protein Therapeutics Summit
May 28, 2014 08:00 ET
|
Amunix Operating Inc.
MOUNTAIN VIEW, CA--(Marketwired - May 28, 2014) - Amunix Operating Inc. today announced the company will present new data from its XTEN half-life extension technology development programs during...
Biogen Idec Signs License Agreement With Amunix for XTENylated Factor VIII
April 21, 2014 08:00 ET
|
Amunix
MOUNTAIN VIEW, CA--(Marketwired - Apr 21, 2014) - Amunix Operating Inc. announced today that Biogen Idec (NASDAQ: BIIB) has exercised its option to enter into an exclusive, worldwide license...
Amunix Announces Expansion to Licensing Agreement With Janssen for Its Proprietary XTEN Technology
January 07, 2014 08:00 ET
|
Amunix
MOUNTAIN VIEW, CA--(Marketwired - Jan 7, 2014) - Amunix Operating Inc. (Amunix) announced today that Janssen Biotech, Inc. (Janssen) has expanded its existing worldwide research collaboration and...